<table border="1" id="id_5cc46249-9b15-460b-b47d-7c7386275410" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_f8c4b5be-44a8-4911-9846-d9324cfcd528">TableÂ 3 Incidence of Primary Endpoint Events</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr id="id_7f177e2f-cbae-47ee-8ef5-a999d0c89792" stylecode="Botrule">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top">Incidence</td>
<td align="center" valign="top">Risk Reduction</td>
<td align="center" valign="top">95% C.I.</td>
<td align="center" valign="top">p-Value</td>
</tr>
</thead>
<tbody>
<tr id="id_ef50d16c-4bee-46c2-9715-c5a4aa6d7515" stylecode="Toprule">
<td align="left" valign="top">
<br/>
</td>
<td align="center" stylecode="Toprule" valign="top">Losartan</td>
<td align="center" stylecode="Toprule" valign="top">Placebo</td>
<td align="center" stylecode="Toprule" valign="top">
<br/>
</td>
<td align="center" stylecode="Toprule" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_0344693d-454c-4403-a4ba-0e4889c1d2e0">
<td align="left" valign="top">
<br/>Primary Composite Endpoint</td>
<td align="center" valign="top">
<br/>43.5%</td>
<td align="center" valign="top">
<br/>47.1%</td>
<td align="center" valign="top">
<br/>16.1%</td>
<td align="center" valign="top">
<br/>2.3% to 27.9%</td>
<td align="center" valign="top">
<br/>0.022</td>
</tr>
<tr id="id_bc81368f-35fe-4a2d-87c2-ee7aa0e544a2">
<td align="left" colspan="6" valign="top">
<br/> Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event</td>
</tr>
<tr id="id_988ce6dc-415e-4364-a9ff-648adbb414aa">
<td align="left" valign="top"> Doubling of Serum Creatinine</td>
<td align="center" valign="top">21.6%</td>
<td align="center" valign="top">26.0%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_c19dd02f-bf7c-4809-81f6-6ff9dc0a7ad6">
<td align="left" valign="top"> ESRD</td>
<td align="center" valign="top">8.5%</td>
<td align="center" valign="top">8.5%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_38b4d8b1-a622-4c2e-a180-b7714e6189e9">
<td align="left" valign="top"> Death</td>
<td align="center" valign="top">13.4%</td>
<td align="center" valign="top">12.6%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_009f9974-44a8-4fad-b009-138722bd36dd">
<td align="left" colspan="6" valign="top">
<br/>Overall Incidence of Doubling of Serum Creatinine, ESRD and Death</td>
</tr>
<tr id="id_5de6cb72-fd65-4c35-b93f-9ce32c328d95">
<td align="left" valign="top">Doubling of Serum Creatinine</td>
<td align="center" valign="top">21.6%</td>
<td align="center" valign="top">26.0%</td>
<td align="center" valign="top">25.3%</td>
<td align="center" valign="top">7.8% to 39.4%</td>
<td align="center" valign="top">0.006</td>
</tr>
<tr id="id_ed2c6b13-9c31-4163-8953-8aa11ed83291">
<td align="left" valign="top">ESRD</td>
<td align="center" valign="top">19.6%</td>
<td align="center" valign="top">25.5%</td>
<td align="center" valign="top">28.6%</td>
<td align="center" valign="top">11.5% to 42.4%</td>
<td align="center" valign="top">0.002</td>
</tr>
<tr id="id_a95fd28c-17bb-45b8-b589-549c5149d830" stylecode="Botrule">
<td align="left" valign="top">Death</td>
<td align="center" valign="top">21.0%</td>
<td align="center" valign="top">20.3%</td>
<td align="center" valign="top">-1.7%</td>
<td align="center" valign="top">-26.9% to 18.6%</td>
<td align="center" valign="top">0.884</td>
</tr>
</tbody>
</table>